The US Preventive Services Task Force conducted a review of trials and cohort studies to support an update of its cervical cancer screening recommendations for women ages 21 to 65 and older.
For the past two decades, meta-analyses have suggested that HPV testing increases detection of pre-cancerous cervical lesions when compared to cytology.
The confirmation of a positive HPV test appeared to be more predictive of a grade 2 or 3 cervical lesion than cytology screening alone.
Pembrolizumab is the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer.
There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.
View a detailed drug treatment regimen chart for cervical cancer, including therapies such as cisplatin, cisplatin + 5-FU, and more.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
Women with HIV are more likely to experience progressive cervical changes, according to a study.
Researchers are evaluating whether DPX-E7 vaccination is safe and will improve outcomes among patients with HPV-positive head and neck, cervical, or anal cancer.
ASCO published global recommendations for the primary prevention of cervical cancer in the Journal of Global Oncology.
Data indicate that the addition of WPR to chemotherapy may provide a survival benefit, though prospective studies are needed to confirm these findings.
Data suggest that adjuvant chemotherapy without radiation may be an effective option for patients with stage IB to IIA cervical cancer with risk factors.
Sentinel lymph node biopsy was associated with fewer surgical complications, less lymphedema, and better quality of life.
BRCA1 and RAD51C methylation in ovarian carcinomas are associated with sensitivity to PARP inhibitors, such as rucaparib.
Although rare, maternal cancer during pregnancy is associated with elevates risks of stillbirth and neonatal death.
A series of 3 articles just published in The Lancet discuss the present and future challenges of breast and cervical cancers globally.
Women vaccinated with earlier versions of the human papillomavirus (HPV) vaccine may only need cervical cancer screening every five years.
Human papillomavirus (HPV)-negative women have low long-term incidence of cervical cancer and cervical intraepithelial neoplasia (CIN).
Researchers argue that combination therapies targeting both mutations in the PI3K pathway and HER2 or hormone receptor overexpression should be evaluated across cancer types.
New guidelines provide clinical practice recommendations for patients with cervical cancer in regions with "basic, limited, enhanced, and maximal" health care resources.
Patients with cervical cancer who receive fosaprepitant in addition to palonosetron and dexamethasone may be less likely to experience emesis and nausea.
Not only may co-testing help detect more cases of invasive cervical cancer, but it also may lower overall health care costs.
Intensity-modulated radiation therapy (IMRT) is associated with fewer gastrointestinal and genitourinary adverse events and improved quality of life.
New guidelines stated that screening with an FDA-approved primary HPV test could substitute cytology-based cervical cancer screening methods.
By identifying patients with cervical cancer as low, intermediate, or high-risk, physicians can determine whether bevacizumab will provide survival benefit.
Adding cediranib to carboplatin and paclitaxel may significantly improve efficacy in treatment of metastatic or recurrent cervical cancer.
Transvaginal sonography (TVS) is comparable to magnetic resonance imaging (MRI) for diagnosing and staging local cervical cancer.
Diabetes mellitus (DM) determined to be an independent unfavorable prognostic factor in Asian patients with early cervical cancer.
The FDA has updated the safety labeling for Hycamtin injection by adding a boxed warning for severe myelosuppression.
Recent decline in cervical intraepithelial neoplasia and adenocarcinoma in situ (CIN2+) lesions were likely due to reduced screening.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML